ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1252

Discontinuation of TNFi Treatment Among Rheumatoid Arthritis Patients with a Molecular Signature of Non-response to Tumor Necrosis Factor-ɑ Inhibitor Therapies
Abstract Number: 1830

Discontinuation of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis and Psoriasis
Abstract Number: 0827

Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Abstract Number: 1217

Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Abstract Number: PP10

Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Abstract Number: 1105

Discovering Variants in Suspected Monogenic Systemic Inflammatory Disease: An Adult Case Series
Abstract Number: 0693

Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy
Abstract Number: 0916

Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
Abstract Number: 1730

Disease Activity and Outcome in Pregnancies of Patients with SpA – Data from the German Pregnancy Register RHEKISS
Abstract Number: 1782

Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies
Abstract Number: 1103

Disease Associations with Very High Serum IgG4 Concentrations: A Retrospective Multi-Center Study
Abstract Number: 1854

Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience
Abstract Number: 1116

Disease Characteristics of Steroid-Induced Spinal Epidural Lipomatosis: A Systematic Review
Abstract Number: 0363

Disease Course and Disease Burden in Patients with Axial Spondyloarthritis: Results from 5-year Multicountry Prospective Observational Study
Abstract Number: 1618

Disease Flares in CANDLE/PRAAS with Dose Reductions of Baricitinib

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].